Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All community members are able to be included in the study.~Exclusion Criteria:~* Allergy to any of the components of the allocated drug regimen

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parallel Treatment (Type: OTHER): Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
- Sequential Treatment (Type: OTHER): Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).